Papers/PMID:24814039
Oral magnesium supplementation decreases C-reactive protein levels in subjects with prediabetes and hypomagnesemia: a clinical randomized double-blind placebo-controlled trial.
Archives of medical research2014The record
2 findings · 1 compound · 2 endpoints
What it reported
How to read these marksWhat moved
2 findings
magnesium(2+) — decreases C-reactive protein concentration
Evidence strength: very limited.Findingreplicated ×4“At the end of follow-up, participants who received magnesium chloride showed higher serum magnesium levels (0.86 ± 0.08 vs. 0.69 ± 0.16 mmol/L, p = 0.002) and lower hsCRP levels (4.8 ± 15.2 vs. 17.1 ± 21.0 nmol/L, p = 0.01) compared with participants in the control group.”
Quoted verbatim from Oral magnesium supplementation decreases C-reactive protein levels in subjects with prediabetes and hypomagnesemia: a clinical randomized double-blind placebo-controlled trial.. - Study
- RCT
- Duration
- 3 months
- Dose
- 30 mL of 5% MgCl2 solution once daily for 3 months
- Population
- Men and non-pregnant women aged 18-65 years with newly diagnosed prediabetes and hypomagnesemia (serum magnesium below 0.74 mmol/L); control group received 0.1% NaHCO3 solution
Oral magnesium supplementation decreases C-reactive protein levels in subjects with prediabetes and hypomagnesemia: a clinical randomized double-blind placebo-controlled trial.2014PMID:2481403910.1016/j.arcmed.2014.04.006Permalink
magnesium(2+) — increases serum magnesium concentration
Evidence strength: very limited.Findingreplicated ×12“At the end of follow-up, participants who received magnesium chloride showed higher serum magnesium levels (0.86 ± 0.08 vs. 0.69 ± 0.16 mmol/L, p = 0.002) and lower hsCRP levels (4.8 ± 15.2 vs. 17.1 ± 21.0 nmol/L, p = 0.01) compared with participants in the control group.”
Quoted verbatim from Oral magnesium supplementation decreases C-reactive protein levels in subjects with prediabetes and hypomagnesemia: a clinical randomized double-blind placebo-controlled trial.. - Study
- RCT
- Duration
- 3 months
- Dose
- 30 mL of 5% MgCl2 solution once daily for 3 months
- Population
- Men and non-pregnant women aged 18-65 years with newly diagnosed prediabetes and hypomagnesemia (serum magnesium below 0.74 mmol/L); control group received 0.1% NaHCO3 solution
Oral magnesium supplementation decreases C-reactive protein levels in subjects with prediabetes and hypomagnesemia: a clinical randomized double-blind placebo-controlled trial.2014PMID:2481403910.1016/j.arcmed.2014.04.006Permalink